Cleo Diagnostics Ltd (COV.AX)

0.1750 +0.0100 (+6.06%) At close: 11:37AM AEST

Cleo Diagnostics Ltd

480 Collins Street
Level 2
Melbourne, VIC 3000
Australia
61 3 9614 0600
https://www.cleodx.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard Allman Ph.D.	CEO & Exec. Director	172.26k	N/A	1960
Dr. Andrew N. Stephens	Chief Scientific Officer & Exec. Director	116.28k	N/A	N/A
Prof. Thomas William Jobling	Lead Medical Advisor & Independent Non-Exec. Director	N/A	N/A	N/A
Ms. Pauline M. Moffatt AAICD, B.Com., BCom, FGIA	Company Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development of non-invasive blood based IVD tests to detect the presence and recurrence of ovarian cancer in Australia. It focuses on the development of triage, recurrence, and screening tests for ovarian cancer detection. The company was incorporated in 2021 and is based in Melbourne, Australia.

Corporate governance

Cleo Diagnostics Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.